|
|
| |
| In-house programs |
| home > strategy > in-house programs |
|
NovaLead Pharma is seeking to develop and market breakthrough products for unmet needs. In order to create balanced pipeline, NovaLead is developing novel chemical entities as well as exploring FDA approved generic drug space for new unmet indications acting through therapeutically significant targets.
Most of the company's products in foreseeable future will be partnered. NovaLead believes that the fastest time to market and commercial opportunity can be achieved through partnerships with large companies that have the necessary infrastructures to develop and sell drugs for relevant therapeutics indications.
The novel chemical entities programs are essentially directed towards various types of cancer and will follow the conventional clinical investigation. VLI27, the lead compound in pancreatic cancer has already achieved proof of concept in animals and is progressing rapidly towards IND filing. For products with more complicated, longer development timelines like the VLI27, the company intends to partner post Phase- I with large pharmaceutical companies. Areas outside of our strategic focus, like anti-fungal may be partnered earlier.
On the other hand, the new indication based product opportunities for FDA approved drugs are low hanging fruits with significantly simpler and shorter clinical investigation requirements. The company plans to advance such discoveries to clinical proof of concept (Phase IIB) by itself because the clinical investigation is limited and less complex, given established toxicity and safety profiles of the candidates. Upon successful Phase-IIB, the company will partner with pharmaceutical companies with infrastructure and the ability to effectively launch products in the market. |
| |
| |
|
|
| |
| Therapeutic focus |
|
| Oncology program > |
| Other unmet needs > |
| |
| Major indications |
|
| Pancreatic cancer |
| Colon cancer |
| Acute Myeloid Leukemia |
| Melanoma |
| Diabetic wound |
| Anti-fungal |
| Diabetic cataract |
| Gas gangrene |
| Malaria |
|
|
|
| |
|
|
